Skip to main content
TipRanks
Go Ultimate75% OFF

Lisata Therapeutics (LSTA) AI Stock Analysis

1,060 Followers
LSTA

Lisata Therapeutics

(NASDAQ:LSTA)

Select Model
Rating:49Neutral
Price Target:$1.00▼(-17.36% Downside)
Action:reiterated
Date:11/14/26

The score is held down primarily by weak financial performance (minimal revenue, large losses, and sustained cash burn despite zero debt). Technicals are mixed with only short-term improvement against a longer-term downtrend, and valuation is constrained by negative earnings and no provided dividend yield. Offsetting these, recent corporate actions (M&A plus ~$225M financing and governance upgrades) materially improve funding runway and strategic positioning but do not remove near-term execution and dilution risk.

Positive Factors
Funding runwayThe approximately $225 million financing materially extends the company’s operating runway and supports advancement of MAR001/005 and MAR002 through Phase 2 milestones. This reduces immediate financing pressure and gives management more time to pursue clinical and regulatory value creation.
Negative Factors
Persistent cash burnSustained negative operating and free cash flow shows that the business is not yet self-funding. Continued clinical investment therefore depends on external capital, making financial progress sensitive to financing needs even after the latest capital raise.

Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%LSTA-40.98%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$10.90M
Dividend Yield
―
Average Volume (3M)
304.44K
Price to Earnings (P/E)
-0.6
Beta (1Y)
0.27
Revenue Growth
-90.65%
EPS Growth
11.37%
Country
US
Employees
21
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Lisata Therapeutics Business Overview & Revenue Model

Company Description

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissu...

Lisata Therapeutics Earnings Call Summary

Earnings Call Date:Nov 06, 2025(Q3-2025)|% Change Since:-48.51%|Next Earnings Date:―
Earnings Call SentimentNeutral

Lisata Therapeutics has made significant progress in its clinical programs and strategic partnerships, reflecting strong operational management and promising trial results. However, the need for additional capital for Phase III trials poses a significant challenge. The market's lack of response to positive developments highlights ongoing investor skepticism or broader market conditions.

Positive Updates

Strategic Alliance with GATC Health
Lisata entered into a strategic alliance with GATC Health to use their advanced AI technology for drug discovery, identifying several development candidates for clinical development in 2026.

Negative Updates

Need for Additional Capital
The company acknowledged the need to raise substantial funds or secure partnerships to support a Phase III trial, highlighting the significant financial challenge ahead.

Company Guidance

During the Lisata Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. They reported a decrease in operating expenses to $4.4 million for the third quarter of 2025, down from $5.3 million in the same period the previous year, marking a 17.3% reduction. Research and development expenses also declined by 22.9% to $2 million. The company reported a net loss of $4.2 million, compared to $4.9 million in the third quarter of 2024. Lisata highlighted their cash and cash equivalents totaling approximately $19 million as of September 30, 2025, with projections to support operations into the first quarter of 2027. Additionally, they discussed their strategic alliance with GATC Health and a nonexclusive global license agreement with Catalent, indicating a promising period ahead with several anticipated milestones.

Lisata Therapeutics Financial Statement Overview

Summary

Financials reflect an early-stage, cash-burning biotech: TTM revenue is extremely small (~$0.1M) with a large net loss (~$17.2M) and negative operating/free cash flow (about -$21.7M TTM). Balance-sheet debt is $0 (a positive), but equity has eroded sharply over time (down to ~$7.6M TTM), indicating ongoing losses and funding dependence.

Income Statement

12Very Negative

Balance Sheet

35Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue100.00K170.00K1.00M000
Gross Profit91.00K24.00K1.00M000
EBITDA-21.83M-17.40M-20.61M-22.98M-56.63M-28.92M
Net Income-17.16M-16.59M-19.98M-20.84M-54.23M-27.47M
Balance Sheet
Total Assets648.41M17.74M35.00M54.69M73.03M97.01M
Cash, Cash Equivalents and Short-Term Investments282.72M15.96M31.25M50.53M69.23M94.97M
Total Debt00137.00K168.00K485.00K714.00K
Total Liabilities56.77M3.14M5.68M6.80M6.71M5.01M
Stockholders Equity7.64M14.86M29.57M48.15M66.58M92.25M
Cash Flow
Free Cash Flow-21.66M-15.98M-19.36M-20.03M-21.45M-22.30M
Operating Cash Flow-21.66M-15.95M-19.36M-20.03M-21.17M-22.25M
Investing Cash Flow72.92M15.09M13.23M10.10M28.91M-54.90M
Financing Cash Flow212.48M599.00K-206.00K385.00K-224.00K85.28M

Lisata Therapeutics Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.21

Price Trends

50DMA1.28Negative
100DMA1.69Negative
200DMA2.86Negative

Market Momentum

MACD-0.02Negative
RSI54.08Neutral
STOCH55.06Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Neutral. The current price of 1.21 is above the 20-day moving average (MA) of 1.06, below the 50-day MA of 1.28, and below the 200-day MA of 2.86, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 54.08 is Neutral, neither overbought nor oversold. The STOCH value of 55.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LSTA.

Lisata Therapeutics Risk Analysis

Lisata Therapeutics disclosed 83 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our activities to review and pursue strategic alternatives may not result in a strategic transaction, and even if we do consummate a strategic transaction, there is no assurance that it will deliver the benefits we expect or enhance stockholder value.Q2, 2026
2.In the event that we do not successfully identify a viable strategic alternative, or consummate such a transaction, or if we are unable to raise sufficient capital to fund our operations, our board of directors may determine to pursue a liquidation and dissolution or other wind down of our business. In such an event, the amount of cash available for distribution to our stockholders, if any, will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.Q2, 2026
3.Although we have commenced legal proceedings against Kuva relating to its breach of the Merger Agreement, we are uncertain if we will be successful in obtaining the termination fee and damages from Kuva.Q2, 2026

Lisata Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

LSTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PCSAPCSA55Neutral$5.20M-0.03-411.08%――-92.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
LSTALSTA49Neutral$13.07M-0.64-164.72%―-90.65%11.37%
CTXRCTXR43Neutral$14.69M-0.25-67.15%――57.48%
APVOAPVO41Neutral$1.08M-0.00-201.49%――99.41%
APLMAPLM37Underperform$51.54M-68.00103.09%―-100.00%99.08%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%LSTAAPVOCTXRPCSAAPLMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
LSTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LSTALisata Therapeutics, Inc.1.21-0.88-42.11%
APVOAptevo0.59-24.07-97.59%
CTXRCitius Pharma0.54-0.40-42.78%
PCSAProcessa Pharmaceuticals, Inc.1.86-4.98-72.81%
APLMApollomics Inc.17.68-3.77-17.58%

Lisata Therapeutics Corporate Events

Delistings and Listing ChangesShareholder Meetings

Lisata Therapeutics Stockholders Approve Equity Plans, Defer Conversion Vote

Neutral
Nov 9, 2026

On November 9, 2026, Lisata Therapeutics stockholders approved the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. The plans reserved 44,764,472 and 3,730,372 common shares, respectively, with specified automatic increases, while th...

Business Operations and StrategyExecutive/Board Changes

Lisata Therapeutics Expands Board, Appoints Independent Director

Positive
Oct 14, 2026

On October 13, 2026, Lisata Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed veteran biopharma executive Jeffrey Farrow as a Class III director, with his initial term running through the 2028 annual meeting...

Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance

Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio

Positive
Sep 17, 2026

On September 17, 2026, Lisata Therapeutics completed a stock‑for‑stock acquisition of Marea Therapeutics, making Marea’s cardioendocrine portfolio the strategic focus of the combined company. The deal significantly reshapes Lisata’s shareholder base,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026